Skip to main content

Table 5 Study design of the four meta-analysed prospective, open, randomised clinical studies in female patients with acute uncomplicated and recurrent cystitis treated with nitroxoline (NTX) versus a control antibiotic, cotrimoxazole (CTX) or norfloxacin (NFX)

From: Review of the literature and individual patients’ data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections

Study

Nitroxoline

Control

Indication

Patients (n)

Duration

End of therapy visit

Test of cure visit

NWNF 10°

Nitroxoline (NTX)

Cotrimoxazole (CTX)

Acute uncompl. cystitis

130 total

5 days

day 6

day 12–14

3×250 mg

2×960 mg

 

67 NTX, 63 CTX

NWNF 11

Nitroxoline (NTX)

Cotrimoxazole (CTX)

Acute uncompl. cystitis

115 total

5 days

day 6

day 12–14

3×250 mg

2×960 mg

 

56 NTX

59 CTX

NWNF 13

Nitroxoline (NTX)

Norfloxacin (NFX)

Acute uncompl. cystitis

105 total

5 days

day 6

day 12–14

3×250 mg

2×400 mg

 

51 NTX

54 NFX

NWNF 15

Nitroxoline (NTX)

Cotrimoxazole (CTX)

Acute episode of uncompl. recurrent cystitis

116 total

10 days

day 11–13*

day 21–23

3×250 mg

2×960 mg

60 NTX

56 CTX

  1. °inclusion criteria missing (no urine cultures reported): total 12, NTX 7, CTX 5 patients (included in safety set only).
  2. *additional visit during therapy: day 6–8.